Cargando…

Treatment of refractory secondary hemophagocytic lymphohistiocytosis with umbilical cord mesenchymal stem cells

Hemophagocytic lymphohistiocytosis (HLH) is an aggressive and life-threatening syndrome of excessive immune activation. Mesenchymal stem cells (MSCs) generate an immunosuppressive microenvironment by secreting cytokines and have been used to treat autoimmune diseases. We report the first case of ref...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiaoyang, Zhang, Shufang, Huang, Denggao, Wang, Zhiming, Chen, Xiaoxia, Luo, Xiansheng, Lei, Meiqing, Yu, Feng, Chen, Xiaobo, Huang, Peilong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567783/
https://www.ncbi.nlm.nih.gov/pubmed/30961409
http://dx.doi.org/10.1177/0300060519836533
_version_ 1783427155489718272
author Yang, Xiaoyang
Zhang, Shufang
Huang, Denggao
Wang, Zhiming
Chen, Xiaoxia
Luo, Xiansheng
Lei, Meiqing
Yu, Feng
Chen, Xiaobo
Huang, Peilong
author_facet Yang, Xiaoyang
Zhang, Shufang
Huang, Denggao
Wang, Zhiming
Chen, Xiaoxia
Luo, Xiansheng
Lei, Meiqing
Yu, Feng
Chen, Xiaobo
Huang, Peilong
author_sort Yang, Xiaoyang
collection PubMed
description Hemophagocytic lymphohistiocytosis (HLH) is an aggressive and life-threatening syndrome of excessive immune activation. Mesenchymal stem cells (MSCs) generate an immunosuppressive microenvironment by secreting cytokines and have been used to treat autoimmune diseases. We report the first case of refractory secondary HLH treated with umbilical cord MSCs. A 52-year-old Chinese female patient with a history of type 2 diabetes was diagnosed with refractory secondary HLH based upon the HLH-2004 protocol and was treated by infusion of third-party umbilical cord MSCs (1.4 × 10(6) cells/kg of body weight, 70 × 10(6) cells in total) from the stem cell bank of Hainan Province. Body temperature recovered to normal on the sixth day after infusion with umbilical cord MSCs, and the levels of inflammatory factors macrophage inflammatory protein (MIP)-1α, interleukin (IL)-12p70, stromal cell-derived factor (SDF)-1α, and IL-7 decreased significantly. Blood glucose levels were significantly lower than before treatment, and the amount of insulin needed was significantly reduced. Umbilical cord MSCs can relieve the symptoms of refractory secondary HLH and have a therapeutic effect on insulin resistance in type 2 diabetes mellitus.
format Online
Article
Text
id pubmed-6567783
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-65677832019-06-20 Treatment of refractory secondary hemophagocytic lymphohistiocytosis with umbilical cord mesenchymal stem cells Yang, Xiaoyang Zhang, Shufang Huang, Denggao Wang, Zhiming Chen, Xiaoxia Luo, Xiansheng Lei, Meiqing Yu, Feng Chen, Xiaobo Huang, Peilong J Int Med Res Clinical Research Reports Hemophagocytic lymphohistiocytosis (HLH) is an aggressive and life-threatening syndrome of excessive immune activation. Mesenchymal stem cells (MSCs) generate an immunosuppressive microenvironment by secreting cytokines and have been used to treat autoimmune diseases. We report the first case of refractory secondary HLH treated with umbilical cord MSCs. A 52-year-old Chinese female patient with a history of type 2 diabetes was diagnosed with refractory secondary HLH based upon the HLH-2004 protocol and was treated by infusion of third-party umbilical cord MSCs (1.4 × 10(6) cells/kg of body weight, 70 × 10(6) cells in total) from the stem cell bank of Hainan Province. Body temperature recovered to normal on the sixth day after infusion with umbilical cord MSCs, and the levels of inflammatory factors macrophage inflammatory protein (MIP)-1α, interleukin (IL)-12p70, stromal cell-derived factor (SDF)-1α, and IL-7 decreased significantly. Blood glucose levels were significantly lower than before treatment, and the amount of insulin needed was significantly reduced. Umbilical cord MSCs can relieve the symptoms of refractory secondary HLH and have a therapeutic effect on insulin resistance in type 2 diabetes mellitus. SAGE Publications 2019-04-08 2019-05 /pmc/articles/PMC6567783/ /pubmed/30961409 http://dx.doi.org/10.1177/0300060519836533 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Clinical Research Reports
Yang, Xiaoyang
Zhang, Shufang
Huang, Denggao
Wang, Zhiming
Chen, Xiaoxia
Luo, Xiansheng
Lei, Meiqing
Yu, Feng
Chen, Xiaobo
Huang, Peilong
Treatment of refractory secondary hemophagocytic lymphohistiocytosis with umbilical cord mesenchymal stem cells
title Treatment of refractory secondary hemophagocytic lymphohistiocytosis with umbilical cord mesenchymal stem cells
title_full Treatment of refractory secondary hemophagocytic lymphohistiocytosis with umbilical cord mesenchymal stem cells
title_fullStr Treatment of refractory secondary hemophagocytic lymphohistiocytosis with umbilical cord mesenchymal stem cells
title_full_unstemmed Treatment of refractory secondary hemophagocytic lymphohistiocytosis with umbilical cord mesenchymal stem cells
title_short Treatment of refractory secondary hemophagocytic lymphohistiocytosis with umbilical cord mesenchymal stem cells
title_sort treatment of refractory secondary hemophagocytic lymphohistiocytosis with umbilical cord mesenchymal stem cells
topic Clinical Research Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6567783/
https://www.ncbi.nlm.nih.gov/pubmed/30961409
http://dx.doi.org/10.1177/0300060519836533
work_keys_str_mv AT yangxiaoyang treatmentofrefractorysecondaryhemophagocyticlymphohistiocytosiswithumbilicalcordmesenchymalstemcells
AT zhangshufang treatmentofrefractorysecondaryhemophagocyticlymphohistiocytosiswithumbilicalcordmesenchymalstemcells
AT huangdenggao treatmentofrefractorysecondaryhemophagocyticlymphohistiocytosiswithumbilicalcordmesenchymalstemcells
AT wangzhiming treatmentofrefractorysecondaryhemophagocyticlymphohistiocytosiswithumbilicalcordmesenchymalstemcells
AT chenxiaoxia treatmentofrefractorysecondaryhemophagocyticlymphohistiocytosiswithumbilicalcordmesenchymalstemcells
AT luoxiansheng treatmentofrefractorysecondaryhemophagocyticlymphohistiocytosiswithumbilicalcordmesenchymalstemcells
AT leimeiqing treatmentofrefractorysecondaryhemophagocyticlymphohistiocytosiswithumbilicalcordmesenchymalstemcells
AT yufeng treatmentofrefractorysecondaryhemophagocyticlymphohistiocytosiswithumbilicalcordmesenchymalstemcells
AT chenxiaobo treatmentofrefractorysecondaryhemophagocyticlymphohistiocytosiswithumbilicalcordmesenchymalstemcells
AT huangpeilong treatmentofrefractorysecondaryhemophagocyticlymphohistiocytosiswithumbilicalcordmesenchymalstemcells